AAPG Ascentage Pharma Group International (Nasdaq ADS) Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
04:48
Jan 14
Jan 14
Ascentage pipeline and cash strong
Ascentage has achieved its 2025 milestones, completed a successful Nasdaq IPO, doubled or tripled its stock price, has sufficient cash through 2027, and its Takeda partnership plus global Phase 3 trial for lead drug validate its R&D and support commercialization in about two years.
HIGH
About AAPG Investor Commentary
Across the available history and selected sources, Buzzberg tracks AAPG (Ascentage Pharma Group International (Nasdaq ADS)) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Dajun Yang.